每经AI快讯，12月23日，盈康生命（300143）在互动平台表示，公司控股股东海尔集团已与蚂蚁集团 签署了全面战略合作协议。作为海尔集团在大健康领域的核心生态平台，公司正积极把握此次合作机 遇，相关协同已在业务层面展开。近期，公司联合蚂蚁健康等生态伙伴，共同启动了AI肿瘤全周期管 理生态平台，旨在通过AI技术为肿瘤用户提供覆盖院前、院中、院后的全病程管理服务。双方的合作 方向主要包括：共同探索构建肿瘤防治生态体系、智慧医院解决方案、家庭医疗软硬件一体化方案以及 高端医疗商保支付等创新模式。目前，公司与蚂蚁集团的相关战略协同尚处于框架协议签署后的初期推 进与具体项目落地阶段，对公司短期业绩尚未产生重大影响。 ...

Core Insights - The core focus of the news is the launch of the AI-driven Tumor Full-Cycle Management Intelligent System by Yingkang Life Technology Co., Ltd., aimed at transforming cancer care through technology and collaboration with various partners [1][3]. Company Developments - Yingkang Life has officially released a strategic product, the Tumor Full-Cycle Management Intelligent System, during the AI Tumor Full-Cycle Health Management Development Forum [1]. - The intelligent system aims to provide each cancer patient with a dedicated AI personal doctor, marking a significant shift from a comprehensive medical group to a technology-driven health solution provider [3]. - The system integrates five core functionalities covering early screening, diagnosis, treatment, rehabilitation, and ecological linkage, utilizing an "online + offline" model to address the entire patient journey [3]. Industry Context - In 2022, approximately 4.8 million new cancer cases were reported in China, accounting for 24% of the global total, highlighting the urgent need for continuous cancer care due to an aging population [4]. - Traditional medical services face challenges such as inefficiencies in hospital visits and difficulties in interpreting medical reports, which the new intelligent system aims to resolve [4]. - The industry consensus is shifting towards a full-cycle systemic paradigm in cancer treatment, moving away from fragmented hospital-centric models [5]. Competitive Advantages - Yingkang Life possesses a unique competitive edge through a combination of resources, technology, and service capabilities, which are difficult for competitors to replicate [6]. - The company operates 11 hospitals and care institutions, creating a comprehensive regional medical center and collaborative network [6]. - The integration of AI and digital strategies has positioned Yingkang Life to leverage extensive real-world data from nearly 200,000 cancer patients annually, enhancing the training of medical AI [6][7]. Technological Innovations - Yingkang Life has initiated a digital transformation strategy, achieving interconnectivity among core systems and establishing a "data lake" for enhanced data utilization [7]. - The company is set to enter the "AI Application 3.0 phase" by early 2025, utilizing advanced AI models to improve healthcare delivery [7]. - The intelligent system is designed to provide personalized and empathetic healthcare services, addressing patient needs effectively [8]. Ecosystem Collaboration - The forum featured contributions from partners like United Imaging Healthcare, Ant Health, and Huimei Technology, emphasizing collaborative efforts in advancing AI in healthcare [9]. - Huimei Technology has developed AI solutions that have been implemented in over 1,200 hospitals, focusing on critical clinical processes in oncology [9]. - Ant Health aims to enhance industry collaboration and provide accessible AI health services, aligning with Yingkang Life's vision for a comprehensive health ecosystem [9]. Future Outlook - The Tumor Health Management Intelligent System platform is expected to be fully operational by 2026, with plans to cover one million cancer patients over the next 3-5 years [10]. - The new strategy is anticipated to lead to a valuation restructuring in the capital market, positioning Yingkang Life as a growth-oriented and scarce investment opportunity [10]. - The "online + offline" integration model is expected to enhance patient satisfaction and operational efficiency, driving revenue growth and long-term sustainability for the company [10].

证券日报网讯 12月23日，盈康生命在互动平台回答投资者提问时表示，截至2025年12月19日，公司股 东总数为20087户。 （文章来源：证券日报） ...

AI肿瘤全周期健康管理生态平台启动） 本报记者 刘钊 12月19日，盈康生命科技股份有限公司（以下简称"盈康生命"）在北京举办"AI肿瘤全周期健康管理发 展论坛"。论坛聚焦人工智能赋能肿瘤防治体系变革，来自政策研究、临床医学、科技企业及产业投资 等多领域的专家学者与生态伙伴，共同探讨AI驱动下肿瘤防控新模式的构建。 盈康生命董事兼总经理马安捷称，"公司使命将变成以科技为驱动，为用户提供全场景、全周期的整合 式的健康管理服务。我们将围绕着肿瘤、血液、居家等场景，在医疗服务和医疗器械双轮驱动的基础 上，以科技创新为底座，构建一个AI驱动下的健康解决方案平台"。有业内人士表示，此举将为公司发 展注入全新动能，且可能颠覆传统医疗服务行业生态。 （盈康生命 与传统的互联网医院模式和线下医院的数字化升级不同，盈康生命肿瘤全周期健康管理智能体真正实现 了线上线下的融合，形成了肿瘤全周期健康管理的新业态。 据了解，盈康生命旗下医院每年服务近20万肿瘤患者。目前，我国肿瘤防治事业面临的系统性挑战，同 时叠加人口老龄化趋势，社会对肿瘤长期、连续照护的需求日益迫切。因而，突破传统以医院为中心 的"片段化"诊疗模式，构建覆盖预防、诊 ...

12月19日，盈康生命科技股份有限公司在北京举办"AI肿瘤全周期健康管理发展论坛"。论坛聚焦人工智能赋能肿瘤防治体系变革，来自政策研究、临 床医学、科技企业及产业投资等多领域的专家学者与生态伙伴，共同探讨AI驱动下肿瘤防控新模式的构建。 与传统的互联网医院模式和线下医院的数字化升级不同，盈康生命肿瘤全周期健康管理智能体真正实现了线上线下的融合，形成了肿瘤全周期健康管 理的新业态。 据了解，盈康生命旗下医院每年服务近20万肿瘤患者。目前，我国肿瘤防治事业面临的系统性挑战，同时叠加人口老龄化趋势，社会对肿瘤长期、连 续照护的需求日益迫切。因而，突破传统以医院为中心的"片段化"诊疗模式，构建覆盖预防、诊断、治疗、康复全周期的系统性新范式已成为行业共 识。 自2025年4月发布AI创新应用平台后，肿瘤健康管理智能体的发布也标志着盈康生命AI战略的再升级，即从AI工具到场景产品的升级。依托该智能 体，盈康生命将于2026年正式对外发布肿瘤垂直领域的APP，未来三到五年预计服务百万计用户量，并围绕患者、医生及药械企业需求开发生态服务 产品，实现生态闭环。 财经频道更多独家策划、专家专栏，免费查阅>>责任编辑：栎树 （盈康 ...

Core Viewpoint - The company is focusing on differentiated development in its medical services sector, aiming to enhance its service capabilities and meet diverse market demands through a multi-layered approach [3][4][5] Group 1: Comprehensive Medical Services - The company is expanding consumer health products and personalized services, transitioning from traditional disease treatment to health management that covers the entire user lifecycle [3][4] - In terms of product offerings, the company is solidifying its full-process service capabilities in core specialties like oncology while actively developing new areas such as chronic disease management, precise anti-aging, scientific weight loss, psychological intervention, and traditional Chinese medicine [3][4] - The company is continuously refining a differentiated service system based on high-quality therapeutic effects to systematically enhance its comprehensive service capabilities [3][4] Group 2: Elderly Care Services - The company is building a collaborative health and wellness service capability centered around the "silver economy," focusing on the needs of severe rehabilitation and elderly care [3][4] - Utilizing its medical institutions' professional resources, the company is developing capabilities to meet rehabilitation and nursing demands while exploring a light-asset operation model [3][4] - The company is also leveraging AI capabilities to improve service accessibility, laying the groundwork for future service scenario expansion [3][4] Group 3: Advanced Medical Services - The company is committed to tracking and introducing cutting-edge diagnostic and treatment technologies and service models to continuously enhance diagnostic levels and patient experiences [3][4] - The aim is to meet the evolving and differentiated needs of users through a layered and focused differentiated layout, ultimately constructing a more comprehensive and resilient medical service system [3][4][5]

证券日报网12月19日讯盈康生命（300143）在12月18日回答调研者提问时表示，公司在AI领域的布局 是系统化、分阶段推进的，目前已构建了从数字化基础到智能化应用的完整路径。具体而言，主要经历 了三个关键阶段：第一阶段，是数字化基础建设。此阶段的核心是完成了包括财务、诊疗、医院管理、 支付结算在内的核心系统的统一与互联互通，为实现全流程数据归集与管理奠定了坚实基础。第二阶 段，是实现数字化治理。在统一的数字底座上，公司实现了院内数据的标准化治理，并初步完成了患者 数据的互联互通，为后续的数据价值挖掘创造了条件。第三阶段，公司聚焦肿瘤全病程管理。在此阶 段，公司系统性地推进从算力支撑、算法模型到智能体应用的技术体系建设，致力于构建以AI驱动为 核心的肿瘤全周期健康管理平台。公司目前已经形成了涵盖技术架构与场景验证的体系化能力，这为 AI技术的持续深化与应用扩展奠定了坚实基础。 ...

证券代码：300143 证券简称：盈康生命 盈康生命科技股份有限公司 投资者关系活动记录表 编号：2025-11 | 投资者关 | □特定对象调研 □分析师会议 | | --- | --- | | 系活动类 | □媒体采访 □业绩说明会 | | 别 | □新闻发布会 路演活动 ☑ | | | □现场参观 | | | 其他（华安证券策略会） | | 参与单位 | 天弘基金 钟颖 李佳豪、工银瑞信基金 李乾宁、民生加银基金 尹 | | 名称及人 涛 | 郝梦娇； | | 员姓名 | 参加华安证券策略会，面向华安证券邀请的投资者，包括 Nature | | | Capital 苗天一、禾晟投资 章孝林、海衍投资 丁威、山西证券 杨 | | | 杰、上海润义投资 陆懿晨、信迹投资 宋文略、绅徽投资 陈彦宁等。 | | 时间 2025 | 年 12 月 18 日 | | 地点 | 路演：天弘基金、工银瑞信基金、民生加银基金公司会议室 | | | 华安证券策略会：陆家嘴富汇大厦 A 座 | | 上市公司 | 董事会秘书 刘泽霖 | | 接待人员 | 投资者关系总监 董丁梦 | | 姓名 | | | | 1、请介绍下公司 ...

Group 1 - The high-pressure oxygen chamber concept increased by 2.20%, ranking fourth among concept sectors, with eight stocks rising, including Jinling Pharmaceutical, BeiYikang, and Innovation Medical, which rose by 6.35%, 5.73%, and 3.79% respectively [1] - The main capital inflow for the high-pressure oxygen chamber concept was 0.29 billion yuan, with five stocks receiving net inflows, led by Innovation Medical with a net inflow of 52.09 million yuan [2][3] - The net inflow ratios for International Medical, Innovation Medical, and Jinling Pharmaceutical were 9.48%, 5.21%, and 3.12% respectively, indicating strong investor interest in these stocks [3] Group 2 - The top gainers in the high-pressure oxygen chamber concept included Innovation Medical, International Medical, and Jinling Pharmaceutical, while the top losers were Samsung Medical and Hangyang Co., which fell by 3.20% and 1.14% respectively [1][4] - The trading volume for Innovation Medical was 11.31%, indicating a high turnover rate, while other stocks like International Medical and Jinling Pharmaceutical had lower turnover rates of 1.77% and 4.54% respectively [3]

证券代码：300143 证券简称：盈康生命 公告编号：2025-048 盈康生命科技股份有限公司 关于 2023 年限制性股票激励计划首次授予部分第二个归属期、 预留授予部分第一个归属期归属结果暨股份上市公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 1、本次归属限制性股票的上市流通日：2025 年 12 月 15 日； 2、本次归属股票数量：1,638,957 股，占归属前上市公司总股本的 0.22%， 其中首次授予部分第二个归属期限制性股票归属数量 1,259,945 股，预留授予部 分第一个归属期归属数量 379,012 股； 3、本次归属人数：173 人，其中首次授予部分第二个归属期归属的激励对 象 153 人，预留授予部分第一个归属期归属的激励对象 20 人； 4、本次归属股票价格：5.08 元/股； 5、本次归属股票来源：公司在二级市场回购的本公司 A 股普通股股票； 2023 年 9 月 12 日，公司召开 2023 年第三次临时股东大会，审议并通过了 1 《关于公司<2023 年限制性股票激励计划（草案）>及其摘要的议案》 ...